Skip to main content
SpringerLink
Log in

Anticoagulation for Venous Thromboembolism

  • Chapter
  • First Online:
Phlebology, Vein Surgery and Ultrasonography

  • 1496 Accesses

Abstract

Anticoagulation is a fundamental of management in venous disease. This chapter discusses anticoagulant therapy and a variety of agents. The current treatment for a new venous thromboembolic event in a patient is anticoagulant therapy, beginning with either unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH), while warfarin is concomitantly initiated for chronic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):160S–98S.

    Article  PubMed  CAS  Google Scholar 

  2. Kim KH, Choi WS, Lee JH, Lee H, Yang DH, Chae SC. Relationship between dietary vitamin K intake and the stability of anticoagulation effect in patients taking long-term warfarin. Thromb Haemost. 2010;104(4):755–9.

    Article  PubMed  CAS  Google Scholar 

  3. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med. 2005;7(2):97–104.

    Article  PubMed  CAS  Google Scholar 

  4. Yang L, Ge W, Yu F, Zhu H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement – a systematic review and meta analysis. Thromb Res. 2010;125(4):e159–66.

    Article  PubMed  CAS  Google Scholar 

  5. White RH, McCurdy SA, von Marensdorff H, Woodruff Jr DE, Leftgoff L. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study. Ann Intern Med. 1989;111(9):730–7.

    Article  PubMed  CAS  Google Scholar 

  6. Ansell J, Holden A, Knapic N. Patient self-management of oral anticoagulation guided by capillary (fingerstick) whole blood prothrombin times. Arch Intern Med. 1989;149(11):2509–11.

    Article  PubMed  CAS  Google Scholar 

  7. Heneghan C, Alonso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet. 2006;367(9508):404–11.

    Article  PubMed  CAS  Google Scholar 

  8. Matchar DB, Jacobson A, Dolor R, Edson R, Uyeda L, Phibbs CS, et al. Effect of home testing of international normalized ratio on clinical events. N Engl J Med. 2010;363(17):1608–20.

    Article  PubMed  CAS  Google Scholar 

  9. Ryan F, Byrne S, O’Shea S. Randomized controlled trial of supervised patient self-testing of warfarin therapy using an internet-based expert system. J Thromb Haemost. 2009;7(8):1284–90.

    Article  PubMed  CAS  Google Scholar 

  10. Schulman S, Beyth RJ, Kearon C, Levine MN. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):257S–98S.

    Article  PubMed  CAS  Google Scholar 

  11. Majeed A, Eelde A, Agren A, Schulman S, Holmstrom M. Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. Thromb Res. 2012;129:146–51.

    Article  PubMed  CAS  Google Scholar 

  12. O’Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295(3):293–8.

    Article  PubMed  Google Scholar 

  13. Bell WR. Present-day thrombolytic therapy: therapeutic agents – pharmacokinetics and pharmacodynamics. Rev Cardiovasc Med. 2002;3 Suppl 2:S34–44.

    PubMed  Google Scholar 

  14. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, Goldhaber SZ, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation. 2011;123(16):1788–830.

    Article  PubMed  Google Scholar 

  15. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):454S–545S.

    Article  PubMed  CAS  Google Scholar 

  16. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prevention du Risqued’EmboliePulmonaire par Interruption Cave Study Group. N Engl J Med. 1998;338(7):409–15.

    Article  PubMed  CAS  Google Scholar 

  17. Mismetti P, Rivron-Guillot K, Quenet S, Decousus H, Laporte S, Epinat M, et al. A prospective long-term study of 220 patients with a retrievable vena cava filter for secondary prevention of venous thromboembolism. Chest. 2007;131(1):223–9.

    Article  PubMed  Google Scholar 

  18. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet. 2003;362(9383):523–6.

    Article  PubMed  Google Scholar 

  19. Douketis J, Tosetto A, Marcucci M, Baglin T, Cosmi B, Cushman M, et al. Risk of recurrence after venous thromboembolism in men and women: patient level meta-analysis. BMJ. 2011;342:d813.

    Article  PubMed  Google Scholar 

  20. Baglin T, Douketis J, Tosetto A, Marcucci M, Cushman M, Kyrle P, et al. Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient-level meta-analysis. J Thromb Haemost. 2010;8(11):2436–42.

    Article  PubMed  CAS  Google Scholar 

  21. Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants’ data from seven trials. BMJ. 2011;342:d3036.

    Article  PubMed  Google Scholar 

  22. Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med. 2003;138(2):128–34.

    Article  PubMed  Google Scholar 

  23. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006;166(7):729–36.

    Article  PubMed  CAS  Google Scholar 

  24. van den Belt AG, Sanson BJ, Simioni P, Prandoni P, Buller HR, Girolami A, et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med. 1997;157(19):2227–32.

    Article  PubMed  Google Scholar 

  25. Brouwer JL, Lijfering WM, Ten Kate MK, Kluin-Nelemans HC, Veeger NJ, van der Meer J. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost. 2009;101(1):93–9.

    PubMed  CAS  Google Scholar 

  26. Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA. 2005;293(19):2352–61.

    Article  PubMed  CAS  Google Scholar 

  27. McRae S, Tran H, Schulman S, Ginsberg J, Kearon C. Effect of patient’s sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet. 2006;368(9533):371–8.

    Article  PubMed  Google Scholar 

  28. Kearon C, Ginsberg JS, Douketis J, Turpie AG, Bates SM, Lee AY, et al. An evaluation of D-dimer in the diagnosis of pulmonary embolism: a randomized trial. Ann Intern Med. 2006;144(11):812–21.

    Article  PubMed  Google Scholar 

  29. Verhovsek M, Douketis JD, Yi Q, Shrivastava S, Tait RC, Baglin T, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med. 2008;149(7):481–90, W94.

    Article  PubMed  Google Scholar 

  30. Douketis J, Tosetto A, Marcucci M, Baglin T, Cushman M, Eichinger S, et al. Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med. 2010;153(8):523–31.

    Article  PubMed  Google Scholar 

  31. Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355(17):1780–9.

    Article  PubMed  CAS  Google Scholar 

  32. Siragusa S, Malato A, Anastasio R, Cigna V, Milio G, Amato C, et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood. 2008;112(3):511–5.

    Article  PubMed  CAS  Google Scholar 

  33. Le Gal G, Carrier M, Kovacs MJ, Betancourt MT, Kahn SR, Wells PS, et al. Residual vein obstruction as a predictor for recurrent thromboembolic events after a first unprovoked episode: data from the REVERSE cohort study. J Thromb Haemost. 2011;9(6):1126–32.

    Article  Google Scholar 

  34. Carrier M, Rodger MA, Wells PS, Righini M, LEG G. Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis. J Thromb Haemost. 2011;9(6):1119–25.

    Article  PubMed  CAS  Google Scholar 

  35. Rodger MA, Kahn SR, Wells PS, Anderson DA, Chagnon I, Le Gal G, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179(5):417–26.

    Article  PubMed  Google Scholar 

  36. Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation. 2010;121(14):1630–6.

    Article  PubMed  Google Scholar 

  37. Kearon C, Ginsberg JS, Kovacs MJ, Anderson DR, Wells P, Julian JA, et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med. 2003;349(7):631–9.

    Article  PubMed  CAS  Google Scholar 

  38. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med. 2003;348(15):1425–34.

    Article  PubMed  CAS  Google Scholar 

  39. Greinacher A, Warkentin TE. The direct thrombin inhibitor hirudin. Thromb Haemost. 2008;99(5):819–29.

    PubMed  CAS  Google Scholar 

  40. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA. 2005;293(6):681–9.

    Article  PubMed  CAS  Google Scholar 

  41. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–51.

    Article  PubMed  CAS  Google Scholar 

  42. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–52.

    Article  PubMed  CAS  Google Scholar 

  43. Schulman S, Eriksson H, Goldhaber SZ, Kakkar AK, Kearon C, Kvamme AM, et al. Dabigatran or warfarin for extended maintenance therapy of venous thromboembolism. J ThrombHaemost. 2011:O-TH-033.

    Google Scholar 

  44. Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–27.

    Article  PubMed  Google Scholar 

  45. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105(2):371–8.

    Article  PubMed  CAS  Google Scholar 

  46. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42:3594–9.

    Article  PubMed  Google Scholar 

  47. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–9.

    Article  PubMed  CAS  Google Scholar 

  48. Orfeo T, Butenas S, Brummel-Ziedins KE, Gissel M, Mann KG. Anticoagulation by factor Xa inhibitors. J Thromb Haemost. 2010;8(8):1745–53.

    Article  PubMed  CAS  Google Scholar 

  49. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510.

    Article  PubMed  CAS  Google Scholar 

  50. Hillarp A, Baghaei F, FagerbergBlixter I, Gustafsson KM, Stigendal L, Sten-Linder M, et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost. 2011;9(1):133–9.

    Article  PubMed  CAS  Google Scholar 

  51. Romualdi E, Rancan E, Siragusa S, Ageno W. Managing bleeding complications in patients treated with the old and the new anticoagulants. Curr Pharm Des. 2010;16(31):3478–82.

    Article  PubMed  CAS  Google Scholar 

  52. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

    Article  PubMed  CAS  Google Scholar 

  53. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365(8):699–708.

    Article  PubMed  CAS  Google Scholar 

  54. Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104(6):1263–71.

    Article  PubMed  CAS  Google Scholar 

  55. Becker RC, Yang H, Barrett Y, Mohan P, Wang J, Wallentin L, et al. Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban – an oral, direct and selective factor Xa inhibitor. J Thromb Thrombolysis. 2011;32(2):183–7.

    Article  PubMed  Google Scholar 

  56. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633–41.

    Article  PubMed  CAS  Google Scholar 

  57. Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, et al. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose–response study. Thromb Haemost. 2010;104(3):642–9.

    Article  PubMed  CAS  Google Scholar 

  58. Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50(7):743–53.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departments of Medicine and Pathology, Duke University Medical Center, Durham, NC, USA

    Thomas L. Ortel MD, PhD

Authors
  1. Thomas L. Ortel MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas L. Ortel MD, PhD .

Editor information

Editors and Affiliations

  1. Vein Specialists of Monterey, Monterey, California, USA

    Eric Mowatt-Larssen

  2. Department of Surgery, University of Texas-Houston Duke University School of Medicine, Houston, Texas, USA

    Sapan S. Desai

  3. MSB 5.030, University of Texas-Houston, Houston, Texas, USA

    Anahita Dua

  4. Vascular Surgery, Duke University Medical Center, Durham, North Carolina, USA

    Cynthia E. K. Shortell

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Ortel, T.L. (2014). Anticoagulation for Venous Thromboembolism. In: Mowatt-Larssen, E., Desai, S., Dua, A., Shortell, C. (eds) Phlebology, Vein Surgery and Ultrasonography. Springer, Cham. https://doi.org/10.1007/978-3-319-01812-6_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-01812-6_21

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-01811-9

  • Online ISBN: 978-3-319-01812-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation